Federal subpoenas are latest in opioid actions.
Approval made via international collaborative effort.
FDA cites 15 companies making unsubstantiated health claims.
PBM mergers contribute to pricing problems, ACP says.
Trump claims lower drug prices, fights Pelosi bill.
FDA and Congress are putting forth new proposals to mitigate drug shortages, which continue to have a major impact on the US healthcare system.
Pharma maker develops biosimilars to Lucentis, Eyelea.
Sandoz now has 2 biosimilars to the popular cancer drug.
Health groups had urged Trump to make a different choice.
PBM’s Medicare plan includes deep discounts